After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...
Please provide your email address to receive an email when new articles are posted on . Despite guidelines recommending early and aggressive therapy in RA, disease-modifying antirheumatic drug ...
Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results